Neuroleptic malignant syndrome

Australian and New Zealand Journal of Psychiatry

Volumn 44, Issue 6, 2010, Pages 584-

  Yasugi, Shinji ^a   Garg, Vikas ^a   Been, Greg ^a   Magoulas, Penny ^a  

^a Mirrabook Adult Psychiatry Inpatient Unit   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; BROMOCRIPTINE; CREATINE KINASE; LITHIUM; QUETIAPINE; RISPERIDONE;

ADULT; BIPOLAR DISORDER; BLURRED VISION; CASE REPORT; CONFUSION; DECISION MAKING; DELUSION; DISORIENTATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; LETTER; LEUKOCYTE COUNT; NEUROLEPTIC MALIGNANT SYNDROME; QT PROLONGATION; RISK FACTOR; SLEEP DISORDER; SPEECH DISORDER; TREMOR;

ADULT; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LITHIUM CARBONATE; NEUROLEPTIC MALIGNANT SYNDROME; RECURRENCE; RISK FACTORS; SULPIRIDE;

EID: 77952795489     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1080/00048671003646769     Document Type: Letter

References (5)

1. Velamoor VR. Neuroleptic malignant syndrome. Recognition, prevention and management. Drus Saf 1998; 19:73-82.
2. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985; 142:1137-1145.
3. American Psychiatric Association. Diagnostic and Statistical Manual of mental disorders. Text Revision 4th Edition Washington DC, 2000.
4. Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164:870-876.
5. Bhanushali MJ, Tuite PJ. The evaluation and management of patients with neuroleptic malignant syndrome. Neurol Clin 2004; 22:389-411.